ArticleJMIR medical informatics2025
Machine Learning for the Prediction of Acute Kidney Injury in Critically Ill Patients With Coronary Heart Disease: Algorithm Development and Validation.
Article in JMIR medical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) frequently occurs in critically ill patients with coronary heart disease (CHD), and its development markedly elevates mortality rates and prolongs hospitalization duration. Early AKI prediction is crucial for timely intervention and amelioration of patient outcomes.
objectiveThis study aimed to develop and verify a clinical prediction model for the occurrence of AKI upon admission in the critically ill population with CHD through machine learning (ML).
methodsData from the MIMIC-IV (Medical Information Mart for Intensive Care IV) version 2.2 database were gathered and included information about critically ill individuals with CHD in the intensive care unit (ICU). The dataset was randomized into a training set (70%) and a testing set (30%). Least absolute shrinkage and selection operator (LASSO) regression was used for feature variable selection. ML models, including logistic regression (LR), decision tree (DT), naive Bayes (NB), random forest (RF), extreme gradient boosting (XGBoost), and support vector machine (SVM), were constructed using 13 variables in the training set. The 6 models were compared in the testing set to identify the best-performing model. Subsequently, the model was assessed using calibration curve analysis and decision curve analysis (DCA). External validation was conducted using data from the Second Affiliated Hospital of Zhengzhou University. Ultimately, the predictive model was interpreted via Shapley Additive Explanation (SHAP) values.
resultsIn total, 2711 patients with CHD admitted to the ICU were selected, with 1809 (66.7%) having AKI. XGBoost exhibited the best performance regarding discrimination (area under the receiver operating characteristic curve [AUROC]=0.765, 95% CI 0.731-0.800), accuracy (0.725), and sensitivity (0.759). External validation using a cohort of 226 patients confirmed the strong generalizability of the XGBoost model (AUROC=0.835, 95% CI 0.782-0.887). Feature importance analyses derived from SHAP values, DT, RF, and XGBoost consistently identified 5 key predictors associated with the development of AKI: mechanical ventilation, use of antiplatelet agents, age, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and acute physiology score III (APSIII).
conclusionsML models can serve as reliable tools for forecasting AKI in the critically ill population with CHD. The XGBoost model is highly accurate and may aid doctors in identifying high-risk individuals for early intervention to lower mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.